{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Farfarae Flos", "MDA-MB-231 cells", "STAT3", "anticancer", "sesquiterpenoid", "triple-negative breast cancer (TNBC)"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31337063", "DateCompleted": {"Year": "2020", "Month": "04", "Day": "06"}, "DateRevised": {"Year": "2020", "Month": "04", "Day": "08"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "07", "Day": "13"}], "Language": ["eng"], "ELocationID": ["278", "10.3390/biom9070278"], "Journal": {"ISSN": "2218-273X", "JournalIssue": {"Volume": "9", "Issue": "7", "PubDate": {"Year": "2019", "Month": "Jul", "Day": "13"}}, "Title": "Biomolecules", "ISOAbbreviation": "Biomolecules"}, "ArticleTitle": "A Sesquiterpenoid from Farfarae Flos Induces Apoptosis of MDA-MB-231 Human Breast Cancer Cells through Inhibition of JAK-STAT3 Signaling.", "Abstract": {"AbstractText": ["Triple-negative breast cancers (TNBCs) are hard-to-treat breast tumors with poor prognosis, which need to be treated by chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is a transcription factor involved in proliferation, metastasis, and invasion of cancer cells. Therefore, research on searching for promising compounds with metabolism that suppress phosphorylation or transcription of STAT3 in TNBC cells is important. Farfarae Flos is well known as a traditional medicine for treating inflammation. However, few studies have shown that sesquiterpenoids from Farfarae Flos have an anticancer effect. In this study, efficient separation methods and an MTT assay were conducted to isolate an anticancer compound from Farfarae Flos against TNBC MDA-MB-231 cells. Here, 7\u03b2-(3-Ethyl-<i>cis</i>-crotonoyloxy)-1\u03b1-(2-methylbutyryloxy)-3,14-dehydro-<i>Z</i>-notonipetranone (ECN), a compound isolated from Farfarae Flos showed a potent cytotoxic effect on MDA-MB-231 cells. ECN inhibited JAK-STAT3 signaling and suppressed the expression of STAT3 target genes. In addition, ECN induced apoptosis through both extrinsic and intrinsic pathways. Furthermore, we investigated that ECN inhibited the growth of tumors by intraperitoneal administration in mice injected with MDA-MB-231 cells. Therefore, ECN can be an effective chemotherapeutic agent for breast cancer treatment."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea."}], "LastName": "Jang", "ForeName": "Hyeri", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea."}], "LastName": "Ko", "ForeName": "Hyejin", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea."}], "LastName": "Song", "ForeName": "Kwangho", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea. kims@snu.ac.kr."}], "LastName": "Kim", "ForeName": "Yeong Shik", "Initials": "YS"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Biomolecules", "NlmUniqueID": "101596414", "ISSNLinking": "2218-273X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Sesquiterpenes"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Cell Survival"}, {"QualifierName": [], "DescriptorName": "Chromatography, High Pressure Liquid"}, {"QualifierName": [], "DescriptorName": "Countercurrent Distribution"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Magnetic Resonance Spectroscopy"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": [], "DescriptorName": "Mice, Nude"}, {"QualifierName": ["drug effects"], "DescriptorName": "Phosphorylation"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Sesquiterpenes"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}, {"QualifierName": ["metabolism"], "DescriptorName": "Triple Negative Breast Neoplasms"}, {"QualifierName": ["chemistry"], "DescriptorName": "Tussilago"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:87\u2013108. doi: 10.3322/caac.21262.", "ArticleIdList": ["10.3322/caac.21262", "25651787"]}, {"Citation": "Sasco A.J., Kaaks R., Little R.E. Breast cancer: Occurrence, risk factors and hormone metabolism. Expert Rev. Anticancer Ther. 2003;3:546\u2013562. doi: 10.1586/14737140.3.4.546.", "ArticleIdList": ["10.1586/14737140.3.4.546", "12934666"]}, {"Citation": "Madigan M.P., Ziegler R.G., Benichou J., Byrne C., Hoover R.N. Proportion of breast cancer cases in the United States explained by well-established risk factors. J. Natl. Cancer. Inst. 1995;87:1681\u20131685. doi: 10.1093/jnci/87.22.1681.", "ArticleIdList": ["10.1093/jnci/87.22.1681", "7473816"]}, {"Citation": "Pike M.C., Spicer D.V., Dahmoush L., Press M.F. Estrogens progestogens normal breast cell proliferation and breast cancer risk. Epidemiol. Rev. 1993;15:17\u201335. doi: 10.1093/oxfordjournals.epirev.a036102.", "ArticleIdList": ["10.1093/oxfordjournals.epirev.a036102", "8405201"]}, {"Citation": "Ades F., Tryfonidis K., Zardavas D. The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches. Ecancermedicalscience. 2017;11:746. doi: 10.3332/ecancer.2017.746.", "ArticleIdList": ["10.3332/ecancer.2017.746", "PMC5481194", "28690677"]}, {"Citation": "Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492\u20132502. doi: 10.1001/jama.295.21.2492.", "ArticleIdList": ["10.1001/jama.295.21.2492", "16757721"]}, {"Citation": "Irvin W.J., Jr., Carey L.A. What is triple-negative breast cancer? Eur. J. Cancer. 2008;44:2799\u20132805. doi: 10.1016/j.ejca.2008.09.034.", "ArticleIdList": ["10.1016/j.ejca.2008.09.034", "19008097"]}, {"Citation": "Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer. 2007;109:1721\u20131728. doi: 10.1002/cncr.22618.", "ArticleIdList": ["10.1002/cncr.22618", "17387718"]}, {"Citation": "Keam B., Im S.A., Lee K.H., Han S.W., Oh D.Y., Kim J.H., Lee S.H., Han W., Kim D.W., Kim T.Y. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13:R22. doi: 10.1186/bcr2834.", "ArticleIdList": ["10.1186/bcr2834", "PMC3219180", "21366896"]}, {"Citation": "Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010;363:1938\u20131948. doi: 10.1056/NEJMra1001389.", "ArticleIdList": ["10.1056/NEJMra1001389", "21067385"]}, {"Citation": "Boyle P. Triple-negative breast cancer: Epidemiological considerations and recommendations. Ann. Oncol. 2012;23:vi7\u2013vi12. doi: 10.1093/annonc/mds187.", "ArticleIdList": ["10.1093/annonc/mds187", "23012306"]}, {"Citation": "Bromberg J., Darnell J.E., Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19:2468\u20132473. doi: 10.1038/sj.onc.1203476.", "ArticleIdList": ["10.1038/sj.onc.1203476", "10851045"]}, {"Citation": "Wang Y., van Boxel-Dezaire A.H., Cheon H., Yang J., Stark G.R. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc. Natl. Acad. Sci. USA. 2013;110:16975\u201316980. doi: 10.1073/pnas.1315862110.", "ArticleIdList": ["10.1073/pnas.1315862110", "PMC3801081", "24082147"]}, {"Citation": "Zhao X., Sun X., Li X.-L. Expression and clinical significance of STAT3, P-STAT3, and VEGF-C in small cell lung cancer. Asian Pac. J. Cancer Prev. 2012;13:2873\u20132877. doi: 10.7314/APJCP.2012.13.6.2873.", "ArticleIdList": ["10.7314/APJCP.2012.13.6.2873", "22938476"]}, {"Citation": "Marrero M.B., Schieffer B., Paxton W.G., Heerdt L., Berk B.C., Delafontaine P., Bernstein K.E. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature. 1995;375:247\u2013250. doi: 10.1038/375247a0.", "ArticleIdList": ["10.1038/375247a0", "7746328"]}, {"Citation": "Vila-Coro A.J., Rodr\u00edguez-frade J.M., Martin De Ana A., Moreno-Ort\u00edz M.C., Mart \u00ednez A.-C., Mellado M. The chemokine SDF-1\u03b1 triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 1999;13:1699\u20131710. doi: 10.1096/fasebj.13.13.1699.", "ArticleIdList": ["10.1096/fasebj.13.13.1699", "10506573"]}, {"Citation": "Ahmad M.K., Srivastava S., Mahdi A.A. Molecular Diagnostics in Cancer Patients. Springer; Singapore: 2019. Molecular Diagnostic in Prostate Cancer; pp. 187\u2013198."}, {"Citation": "Yang E., Wen Z.L., Haspel R.L., Zhang J.J., Darnell J.E. The linker domain of Stat1 is required for gamma interferon-driven transcription. Mol. Cell. Biol. 1999;19:5106\u20135112. doi: 10.1128/MCB.19.7.5106.", "ArticleIdList": ["10.1128/MCB.19.7.5106", "PMC84353", "10373559"]}, {"Citation": "Yu C.L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., Jove R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81\u201383. doi: 10.1126/science.7541555.", "ArticleIdList": ["10.1126/science.7541555", "7541555"]}, {"Citation": "Ma H., Yan D., Wang Y., Shi W., Liu T., Zhao C., Huo S., Duan J., Tao J., Zhai M. Bazedoxifene exhibits growth suppressive activity by targeting IL-6/GP130/STAT3 signaling in hepatocellular carcinoma. Cancer Sci. 2019;2019. 110:950\u2013961. doi: 10.1111/cas.13940.", "ArticleIdList": ["10.1111/cas.13940", "PMC6398888", "30648776"]}, {"Citation": "Jiang X., Tang J., Wu M., Chen S., Xu Z., Wang H., Wang H., Yu X., Li Z., Teng L. BP-1-102 exerts an antitumor effect on the AGS human gastric cancer cell line through modulating the STAT3 and MAPK signaling pathways. Mol. Med. Rep. 2019;19:2698\u20132706. doi: 10.3892/mmr.2019.9892.", "ArticleIdList": ["10.3892/mmr.2019.9892", "PMC6423579", "30720080"]}, {"Citation": "Jing N., Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs. 2005;16:601\u2013607. doi: 10.1097/00001813-200507000-00002.", "ArticleIdList": ["10.1097/00001813-200507000-00002", "15930886"]}, {"Citation": "Song H., Wang R., Wang S., Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA. 2005;102:4700\u20134705. doi: 10.1073/pnas.0409894102.", "ArticleIdList": ["10.1073/pnas.0409894102", "PMC555708", "15781862"]}, {"Citation": "Pathak A.K., Bhutani M., Nair A.S., Ahn K.S., Chakraborty A., Kadara H., Guha S., Sethi G., Aggarwal B.B. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol. Cancer Res. 2007;5:943\u2013955. doi: 10.1158/1541-7786.MCR-06-0348.", "ArticleIdList": ["10.1158/1541-7786.MCR-06-0348", "17855663"]}, {"Citation": "Sherry M.M., Reeves A., Wu J.K., Cochran B.H. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009;27:2383\u20132392. doi: 10.1002/stem.185.", "ArticleIdList": ["10.1002/stem.185", "PMC4391626", "19658181"]}, {"Citation": "Garcia R., Yu C.-L., Hudnall A., Catlett R., Nelson K.L., Smithgall T., Fujita D.J., Ethier S.P., Jove R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997;8:1267\u20131275.", "ArticleIdList": ["9419415"]}, {"Citation": "Dechow T.N., Pedranzini L., Leitch A., Leslie K., Gerald W.L., Linkov I., Bromberg J.F. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. USA. 2004;101:10602\u201310607. doi: 10.1073/pnas.0404100101.", "ArticleIdList": ["10.1073/pnas.0404100101", "PMC489981", "15249664"]}, {"Citation": "Liu L., Nam S., Tian Y., Yang F., Wu J., Wang Y., Scuto A., Polychronopoulos P., Magiatis P., Skaltsounis L. 6-Bromoindirubin-3\u2032-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res. 2011;71:3972\u20133979. doi: 10.1158/0008-5472.CAN-10-3852.", "ArticleIdList": ["10.1158/0008-5472.CAN-10-3852", "PMC3107399", "21610112"]}, {"Citation": "Sansone P., Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 2012;30:1005\u20131014. doi: 10.1200/JCO.2010.31.8907.", "ArticleIdList": ["10.1200/JCO.2010.31.8907", "PMC3341105", "22355058"]}, {"Citation": "Zhao M., Jiang B., Gao F.H. Small molecule inhibitors of STAT3 for cancer therapy. Curr. Med. Chem. 2011;18:4012\u20134018. doi: 10.2174/092986711796957284.", "ArticleIdList": ["10.2174/092986711796957284", "21824090"]}, {"Citation": "Zhao Z., Xiao P. Encyclopedia of Medicinal Plants. Volume 3. World Publishing Corporation; Beijing, China: 2009. Asteraceae; pp. 492\u2013493."}, {"Citation": "Zhao J., Evangelopoulos D., Bhakta S., Gray A.I., Seidel V. Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents. J. Ethnopharmacol. 2014;155:796\u2013800. doi: 10.1016/j.jep.2014.06.034.", "ArticleIdList": ["10.1016/j.jep.2014.06.034", "24955560"]}, {"Citation": "Kikuchi M., Suzuki N. Studies on the constituents of Tussilago farfara L. II. Structures of new sesquiterpenoids isolated from the flower buds. Chem. Pharm. Bull. 1992;40:2753\u20132755. doi: 10.1248/cpb.40.2753.", "ArticleIdList": ["10.1248/cpb.40.2753"]}, {"Citation": "Wu D., Zhang M., Zhang C., Wang Z. Flavonoids and phenolic acid derivatives from Flos Farfarae. Chin. J. Chin. Mater. Med. 2010;35:1142\u20131144.", "ArticleIdList": ["20707069"]}, {"Citation": "Yaoita Y., Kamazawa H., Kikuchi M. Structures of new oplopane-type sesquiterpenoids from the flower buds of Tussilago farfara L. Chem. Pharm. Bull. 1999;47:705\u2013707. doi: 10.1248/cpb.47.705.", "ArticleIdList": ["10.1248/cpb.47.705"]}, {"Citation": "Li W., Huang X., Yang X.W. New sesquiterpenoids from the dried flower buds of Tussilago farfara and their inhibition on NO production in LPS-induced RAW264.7 cells. Fitoterapia. 2012;83:318\u2013322. doi: 10.1016/j.fitote.2011.11.011.", "ArticleIdList": ["10.1016/j.fitote.2011.11.011", "22120501"]}, {"Citation": "Cho J., Kim H.M., Ryu J.H., Jeong Y.S., Lee Y.S., Jin C. Neuroprotective and antioxidant effects of the ethyl acetate fraction prepared from Tussilago farfara L. Biol. Pharm. Bull. 2005;28:455\u2013460. doi: 10.1248/bpb.28.455.", "ArticleIdList": ["10.1248/bpb.28.455", "15744068"]}, {"Citation": "Lee K.M., Kwon T.Y., Kang U., Seo E.K., Yun J.H., Nho C.W., Kim Y.S. Tussilagonone-induced Nrf2 pathway activation protects HepG2 cells from oxidative injury. Food Chem. Toxicol. 2017;108:120\u2013127. doi: 10.1016/j.fct.2017.07.035.", "ArticleIdList": ["10.1016/j.fct.2017.07.035", "28733231"]}, {"Citation": "Song K., Lee K.J., Kim Y.S. Development of an efficient fractionation method for the preparative separation of sesquiterpenoids from Tussilago farfara by counter-current chromatography. J. Chromatogr. A. 2017;1489:107\u2013114. doi: 10.1016/j.chroma.2017.02.005.", "ArticleIdList": ["10.1016/j.chroma.2017.02.005", "28215402"]}, {"Citation": "Pellegrini S., Dusanter-Fourt I. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs) FEBS J. 1997;248:615\u2013633. doi: 10.1111/j.1432-1033.1997.00615.x.", "ArticleIdList": ["10.1111/j.1432-1033.1997.00615.x", "9342212"]}, {"Citation": "Carpenter R., Lo H.-W. STAT3 target genes relevant to human cancers. Cancers. 2014;6:897\u2013925. doi: 10.3390/cancers6020897.", "ArticleIdList": ["10.3390/cancers6020897", "PMC4074809", "24743777"]}, {"Citation": "Koopman G., Reutelingsperger C., Kuijten G., Keehnen R., Pals S., Van Oers M. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415\u20131420.", "ArticleIdList": ["8068938"]}, {"Citation": "Bertucci F., Birnbaum D. Reasons for breast cancer heterogeneity. J. Biol. 2008;7:6. doi: 10.1186/jbiol67.", "ArticleIdList": ["10.1186/jbiol67", "PMC2263121", "18304379"]}, {"Citation": "Gluz O., Nitz U., Harbeck N., Ting E., Kates R., Herr A., Lindemann W., Jackisch C., Berdel W., Kirchner H. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial. Ann. Oncol. 2008;19:861\u2013870. doi: 10.1093/annonc/mdm551.", "ArticleIdList": ["10.1093/annonc/mdm551", "18174609"]}, {"Citation": "McDaniel J.M., Varley K.E., Gertz J., Savic D.S., Roberts B.S., Bailey S.K., Shevde L.A., Ramaker R.C., Lasseigne B.N., Kirby M.K. Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget. 2017;8:8226\u20138238. doi: 10.18632/oncotarget.14153.", "ArticleIdList": ["10.18632/oncotarget.14153", "PMC5352396", "28030809"]}, {"Citation": "Chun J., Kim Y.S. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways. Chem. Biol. Interact. 2013;205:212\u2013221. doi: 10.1016/j.cbi.2013.07.002.", "ArticleIdList": ["10.1016/j.cbi.2013.07.002", "23867902"]}, {"Citation": "Chun J., Li R.-J., Cheng M.-S., Kim Y.S. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. Cancer Lett. 2015;357:393\u2013403. doi: 10.1016/j.canlet.2014.11.049.", "ArticleIdList": ["10.1016/j.canlet.2014.11.049", "25434800"]}, {"Citation": "Chun J., Park M.K., Ko H., Lee K., Kim Y.S. Bioassay-guided isolation of cantharidin from blister beetles and its anticancer activity through inhibition of epidermal growth factor receptor-mediated STAT3 and Akt pathways. J. Nat. Med. 2018;72:937\u2013945. doi: 10.1007/s11418-018-1226-6.", "ArticleIdList": ["10.1007/s11418-018-1226-6", "30043217"]}, {"Citation": "Ko H., Lee J.H., Kim H.S., Kim T., Han Y.T., Suh Y.G., Chun J., Kim Y.S., Ahn K.S. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer. Biomolecules. 2019;9:170. doi: 10.3390/biom9050170.", "ArticleIdList": ["10.3390/biom9050170", "PMC6571922", "31058868"]}, {"Citation": "Lee J., Song K., Huh E., Oh M.S., Kim Y.S. Neuroprotection against 6-OHDA toxicity in PC12 cells and mice through the Nrf2 pathway by a sesquiterpenoid from Tussilago farfara. Redox Biol. 2018;18:6\u201315. doi: 10.1016/j.redox.2018.05.015.", "ArticleIdList": ["10.1016/j.redox.2018.05.015", "PMC6041377", "29890337"]}, {"Citation": "Jang H., Lee J.W., Lee C., Jin Q., Choi J.Y., Lee D., Han S.B., Kim Y., Hong J.T., Lee M.K. Sesquiterpenoids from Tussilago farfara inhibit LPS-induced nitric oxide production in macrophage RAW 264.7 cells. Arch. Pharm. Res. 2016;39:127\u2013132. doi: 10.1007/s12272-015-0667-7.", "ArticleIdList": ["10.1007/s12272-015-0667-7", "26474586"]}, {"Citation": "Park H.R., Yoo M.Y., Seo J.H., Kim I.S., Kim N.Y., Kang J.Y., Cui L., Lee C.S., Lee C.-H., Lee H.S. Sesquiterpenoids isolated from the flower buds of Tussilago farfara L. inhibit diacylglycerol acyltransferase. J. Agric. Food Chem. 2008;56:10493\u201310497. doi: 10.1021/jf801978r.", "ArticleIdList": ["10.1021/jf801978r", "18937486"]}, {"Citation": "Kundu J., Choi B.Y., Jeong C.H., Kundu J.K., Chun K.-S. Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2-and Src-mediated phosphorylation of EGF receptor tyrosine kinase. Oncol. Rep. 2014;32:821\u2013828. doi: 10.3892/or.2014.3223.", "ArticleIdList": ["10.3892/or.2014.3223", "24890449"]}, {"Citation": "Coleman M.L., Sahai E.A., Yeo M., Bosch M., Dewar A., Olson M.F. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat. Cell Biol. 2001;3:339\u2013345. doi: 10.1038/35070009.", "ArticleIdList": ["10.1038/35070009", "11283606"]}]}], "History": [{"Year": "2019", "Month": "6", "Day": "7"}, {"Year": "2019", "Month": "7", "Day": "10"}, {"Year": "2019", "Month": "7", "Day": "11"}, {"Year": "2019", "Month": "7", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "7", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "4", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "7", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["31337063", "PMC6681226", "10.3390/biom9070278", "biom9070278"]}}]}